CN113502302A - Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol - Google Patents
Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol Download PDFInfo
- Publication number
- CN113502302A CN113502302A CN202110877954.0A CN202110877954A CN113502302A CN 113502302 A CN113502302 A CN 113502302A CN 202110877954 A CN202110877954 A CN 202110877954A CN 113502302 A CN113502302 A CN 113502302A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- difluorophenyl
- chloro
- biosynthesis
- ketoreductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
Abstract
The invention discloses a biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, which comprises the following steps: carrying out mutation treatment on the ketoreductase wild type gene, adding enzyme cutting sites, preparing recombinant plasmids, introducing a strain, and carrying out secretion, expression and reaction on the strain. The biosynthesis method provided by the invention has the advantages of lower cost and higher selectivity.
Description
Technical Field
The invention relates to the technical field of biosynthesis, in particular to a biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol.
Background
Ticagrelor (also known as ticagrelor) is a new generation of anticoagulant drug developed by astrazepam, is used for antithrombotic treatment after acute coronary syndrome and stent placement, and is approved by FDA in the united states for marketing in 2011. Compared with the current first-line clinical medicine clopidogrel, ticagrelor has the advantages that the ticagrelor can directly take effect after being taken, and the platelet function can be quickly recovered and the cardiovascular death and myocardial infarction can be reduced after the medicine is stopped, so that the clopidogrel has good market prospect. The synthesis route of the drug is reported in the U.S. Pat. No. 5,7250419, and an intermediate 10 (shown in the following figure) is one of three key intermediates for synthesizing ticagrelor, and has high economic value. As described in US7067663, intermediate 10 can be synthesized by asymmetric cyclopropanation of menthol as a chiral prosthetic group, but at high cost. There is also a patent (EP2589587a1) which reports a process for the preparation of intermediate 10 from nitroketones, with ketoreductases as catalysts, but with low product yields and chirality values of only 80%. Another route reported in EP2589587a1 is to obtain (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol (chiral chlorohydrin) by CBS catalytic reduction, but the chiral value is only 90-93%, repeated purifications are required, and the catalyst is expensive. CN109112166A reports that the use of a bio-enzyme catalyst instead of CBS for synthesizing chiral chlorohydrin has mild reaction and reduced cost, but the concentration of a substrate is still not high enough (50-100 g/L), the reaction time is long, and the chiral value still needs to be improved (generally, the chiral product needs to be more than or equal to 99.5%). In summary, there is a need in the art for a less costly and more selective method for synthesizing chiral chlorohydrins.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The invention is proposed in view of the above and/or problems existing in the existing ticagrelor intermediate preparation methods.
Therefore, one of the purposes of the present invention is to overcome the defects of the existing ticagrelor intermediate preparation method, and provide a biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol.
To solve the above technical problem, according to an aspect of the present invention, the present invention provides the following technical solutions: a method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol comprising the steps of:
carrying out mutation treatment on ketoreductase wild type genes: performing mutation treatment on the ketoreductase gene and the gene sequence of the ketoreductase as shown in Seq ID No.1 to obtain a ketoreductase mutant gene, wherein the gene sequence of the ketoreductase mutant is shown in Seq ID No. 2.
Adding enzyme cutting sites: inserting double enzyme cutting sites into a ketoreductase mutant gene;
preparing a recombinant plasmid: inserting the ketoreductase mutant gene into an expression vector to obtain a recombinant plasmid;
introducing a strain: introducing the recombinant plasmid with the ketoreductase gene into a strain to obtain a recombinant expression strain;
secretion and expression of the strains: inducing the recombinant expression strain in a culture solution for expression and then collecting an enzyme solution;
reaction: the enzyme solution is put into a water/organic biphase system to react to prepare (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in the mutation treatment of the ketoreductase wild-type gene, the mutation treatment is carried out by error-prone PCR.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: among the added restriction sites, the double restriction sites were NdeI/HindIII.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in preparing the recombinant plasmid, the expression vector was pET21a (+) 22.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: introduced into a strain BL21(DE 3).
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in the secretion and expression of the strain, the culture solution is an LB culture medium.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in the secretion and expression of the strain, induction culture is also included, when OD is in the culture medium600After 1.0, 0.2mM IPTG was added and the temperature was maintained at 30 ℃.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in the reaction, the water/organic two-phase system is a water/organic two-way system formed by mutually dissolving 40% of water and 60% of ethanol by mass fraction.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: in the reaction, NADP is also included in the reaction system.
The present invention provides a method for biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, wherein: the concentration of NADP is maintained at 0.05-1.0 mM.
The invention provides a biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, which has the advantages of lower cost and better selectivity.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
fig. 1 is a process diagram of synthesizing a key chiral intermediate (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol of ticagrelor in the present invention.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention more comprehensible, specific embodiments thereof are described in detail below with reference to examples of the specification.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
Example 1
The specific principle of the design of the invention is that ketoreductase mutator is used for synthesizing ticagrelor key chiral neutral (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, the specific reaction process is shown in figure 1, the ketoreductase mutator is derived from wild ketomutator, and the specific synthesis method comprises the following steps: the method comprises the steps of adding enzyme cutting sites NdeI/HindIII into a ketoreductase wild gene shown as Seq ID No.1 or a ketoreductase mutant gene shown as Seq ID No.2 at two points, carrying out DNA enzyme cutting purification, inserting the product into an expression vector pET21a (+)22 to obtain a recombinant plasmid, and transforming the recombinant plasmid into BL21(DE3) to construct a recombinant expression strain. Culturing the recombinant strain in LB culture medium to OD600After 1.0, 0.2mM IPTG was added and induced culture was carried out at 30 ℃ for 4 to 5 hours, and the cells were collected by centrifugation and disrupted by sonication to give a crude enzyme solution of wild type or mutant. Adding the crude enzyme solution into a water/organic two-way system in which 40% of water and 60% of ethanol are mutually soluble in mass fraction, and simultaneously maintaining the NADP concentration of 0.05-1.0 mM in the system for reaction.
Example 2
The preparation method of the wild type keto mutant comprises the following steps:
as shown in Seq ID No.1, a ketoreductase wild gene sequence of Saccharomyces cerevisiae (Saccharomyces cerevisiae) is introduced into random mutation and/or introduced point saturation mutation based on enzyme protein structure/simulated substrate docking in an error-prone PCR mode, and then high-throughput screening is carried out to obtain a wild type ketomutator shown in Seq ID No.2 in the invention.
A protein sequence obtained by transcription and translation of a ketoreductase wild gene of Saccharomyces cerevisiae (Saccharomyces cerevisiae) is shown as Seq ID No.3, a protein sequence obtained by translation of a wild type ketomutant is shown as Seq ID No.4, compared with the ketoreductase wild gene, the wild type ketomutant has the difference that phenylalanine at position 87 is mutated into tyrosine, cysteine at position 130 is mutated into threonine or leucine or methionine, isoleucine at position 134 is mutated into methionine, tyrosine at position 165 is mutated into isoleucine, lysine at position 171 is mutated into arginine or histidine, leucine at position 198 is mutated into tryptophan or histidine, and Seq ID No.4 shows the possibility of one protein sequence, but the possibility of mutation of other various protein sequences has the same performance.
Except for Seq ID No.2, the wild type ketone group mutant gene is changed into TAT at 259-261, CTA or ATG at 388-390, ATG at 400-402, ATT at 498-599, CGT or CAT at 211-513, TGG or CAT at 598-600, and any change of any site is also included.
Example 3
Adding a ketoreductase mutant enzyme solution obtained by induced culture into a water/organic phase two-phase system, rechecking the generation process in the example 1 under the assistance of a high-efficiency coenzyme regeneration system consisting of glucose dehydrogenase/glucose, and measuring the obtained substrate conversion rate and the product chiral rate, wherein the obtained substrate conversion rate is more than 99.5 percent after multiple experiments, the highest conversion rate is 99.9 percent, the chiral value of the product is more than 99.5 percent after multiple experiments, and the percentage of the highest chiral value is more than 99.5 percent.
Example 4
The substrate conversion during the reaction was measured as follows: taking 200 microliter to 800 microliter of solvent from the reaction solution, oscillating, mixing, centrifuging, continuously diluting the supernatant in acetonitrile, and carrying out sample injection analysis. Using Agilent 5TC-C18 (250X 4.6mm), the detection wavelength was 264nm, the flow rate was 1.0mL/min, the column temperature was 15 ℃, and the mobile phase was acetonitrile: water 45: 55 (V/V). The substrate peak time was 8.20 minutes and the product peak time was 11.63 minutes. The chiral value of the product was measured as follows: the product was analyzed by making a 0.1mg/ml sample with mobile phase, using CHIRALPAK IA (150X 4.6mm, 5 μm) chiral column, measuring wavelength 264nm, flow rate 1.0ml/min, column temperature 15 ℃, mobile phase n-hexane: ethanol 98: 2 (V/V). The R-isomer peak time was 13.52 minutes and the S-isomer peak time was 11.73 minutes.
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Sequence listing
<110> Jiangxi Keyuan biological shares Ltd
<120> biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1035
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atgtctaata cagttctagt ttctggcgct tcaggtttta ttgccttgca tatcctgtca 60
caattgttaa aacaagatta taaggttatt ggaactgtga gatcccatga aaaagaagca 120
aaattgctaa gacaatttca acataaccct aatttaactt tagaaattgt tccggacatt 180
tctcatccaa atgctttcga taaggttctg cagaaacgtg gacgtgagat taggtatgtt 240
ctacacacgg cctctccttt tcattatgat actaccgaat atgaaaaaga cttattgatt 300
cccgcgttag aaggtacaaa aaacatccta aattctatca agaaatatgc agcagacact 360
gtagagcgtg ttgttgtgac ttcttcttgt actgctatta taacccttgc aaagatggac 420
gatcccagtg tggtttttac agaagagagt tggaacgaag caacctggga aagctgtcaa 480
attgatggga taaatgctta ctttgcatcc aagaagtttg ctgaaaaggc tgcctgggag 540
ttcacaaaag agaatgaaga tcacatcaaa ttcaaactaa caacagtcaa cccttctctt 600
ctttttggtc ctcaactttt cgatgaagat gtgcatggcc atttgaatac ttcttgcgaa 660
atgatcaatg gcctaattca taccccagta aatgccagtg ttcctgattt tcattccatt 720
tttattgatg taagggatgt ggccctagct catctgtatg ctttccagaa ggaaaatacc 780
gcgggtaaaa gattagtggt aactaacggt aaatttggaa accaagatat cctggatatt 840
ttgaacgaag attttccaca attaagaggt ctcattcctt tgggtaagcc tggcacaggt 900
gatcaagtca ttgaccgcgg ttcaactaca gataatagtg caacgaggaa aatacttggc 960
tttgagttca gaagtttaca cgaaagtgtc catgatactg ctgcccaaat tttgaagaag 1020
cagaacagat tatga 1035
<210> 2
<211> 974
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
aattgttaaa acaagattat aaggttattg gaactgtgag atcccatgaa aaagaagcaa 60
aattgctaag acaatttcaa cataacccta atttaacttt agaaattgtt ccggacattt 120
ctcatccaaa tgctttcgat aaggttctgc agaaacgtgg acgtgagatt aggtatgttc 180
tacacacggc ctctccttat cattatgata ctaccgaata tgaaaaagac ttattgattc 240
ccgcgttaga aggtacaaaa aacatcctaa attctatcaa gaaatatgca gcagacactg 300
tagagcgtgt tgttgtgact tcttctctaa ctgctattat gacccttgca aagatggacg 360
atcccagtgt ggtttttaca gaagagagtt ggaacgaagc aacctgggaa agctgtcaaa 420
ttgatgggat aaatgctatt tttgcatccc gtaagtttgc tgaaaaggct gcctgggagt 480
tcacaaaaga gaatgaagat cacatcaaat tcaaactaac aacagtcaac ccttcttggc 540
tttttggtcc tcaacttttc gatgaagatg tgcatggcca tttgaatact tcttgcgaaa 600
tgatcaatgg cctaattcat accccagtaa atgccagtgt tcctgatttt cattccattt 660
ttattgatgt aagggatgtg gccctagctc atctgtatgc tttccagaag gaaaataccg 720
cgggtaaaag attagtggta actaacggta aatttggaaa ccaagatatc ctggatattt 780
tgaacgaaga ttttccacaa ttaagaggtc tcattccttt gggtaagcct ggcacaggtg 840
atcaagtcat tgaccgcggt tcaactacag ataatagtgc aacgaggaaa atacttggct 900
ttgagttcag aagtttacac gaaagtgtcc atgatactgc tgcccaaatt ttgaagaagc 960
agaacagatt atga 974
<210> 3
<211> 344
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Met Ser Asn Thr Val Leu Val Ser Gly Ala Ser Gly Phe Ile Ala Leu
1 5 10 15
His Ile Leu Ser Gln Leu Leu Lys Gln Asp Tyr Lys Val Ile Gly Thr
20 25 30
Val Arg Ser His Glu Lys Glu Ala Lys Leu Leu Arg Gln Phe Gln His
35 40 45
Asn Pro Asn Leu Thr Leu Glu Ile Val Pro Asp Ile Ser His Pro Asn
50 55 60
Ala Phe Asp Lys Val Leu Gln Lys Arg Gly Arg Glu Ile Arg Tyr Val
65 70 75 80
Leu His Thr Ala Ser Pro Phe His Tyr Asp Thr Thr Glu Tyr Glu Lys
85 90 95
Asp Leu Leu Ile Pro Ala Leu Glu Gly Thr Lys Asn Ile Leu Asn Ser
100 105 110
Ile Lys Lys Tyr Ala Ala Asp Thr Val Glu Arg Val Val Val Thr Ser
115 120 125
Ser Cys Thr Ala Ile Ile Thr Leu Ala Lys Met Asp Asp Pro Ser Val
130 135 140
Val Phe Thr Glu Glu Ser Trp Asn Glu Ala Thr Trp Glu Ser Cys Gln
145 150 155 160
Ile Asp Gly Ile Asn Ala Tyr Phe Ala Ser Lys Lys Phe Ala Glu Lys
165 170 175
Ala Ala Trp Glu Phe Thr Lys Glu Asn Glu Asp His Ile Lys Phe Lys
180 185 190
Leu Thr Thr Val Asn Pro Ser Leu Leu Phe Gly Pro Gln Leu Phe Asp
195 200 205
Glu Asp Val His Gly His Leu Asn Thr Ser Cys Glu Met Ile Asn Gly
210 215 220
Leu Ile His Thr Pro Val Asn Ala Ser Val Pro Asp Phe His Ser Ile
225 230 235 240
Phe Ile Asp Val Arg Asp Val Ala Leu Ala His Leu Tyr Ala Phe Gln
245 250 255
Lys Glu Asn Thr Ala Gly Lys Arg Leu Val Val Thr Asn Gly Lys Phe
260 265 270
Gly Asn Gln Asp Ile Leu Asp Ile Leu Asn Glu Asp Phe Pro Gln Leu
275 280 285
Arg Gly Leu Ile Pro Leu Gly Lys Pro Gly Thr Gly Asp Gln Val Ile
290 295 300
Asp Arg Gly Ser Thr Thr Asp Asn Ser Ala Thr Arg Lys Ile Leu Gly
305 310 315 320
Phe Glu Phe Arg Ser Leu His Glu Ser Val His Asp Thr Ala Ala Gln
325 330 335
Ile Leu Lys Lys Glu Asn Arg Leu
340
<210> 4
<211> 343
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Met Ser Asn Thr Val Leu Val Ser Gly Ala Ser Gly Phe Ile Ala Leu
1 5 10 15
His Ile Leu Ser Gln Leu Leu Lys Gln Asp Tyr Lys Val Ile Gly Thr
20 25 30
Val Arg Ser His Glu Lys Glu Ala Lys Leu Leu Arg Gln Phe Gln His
35 40 45
Asn Pro Asn Leu Thr Leu Glu Ile Val Pro Asp Ile Ser His Pro Asn
50 55 60
Ala Phe Asp Lys Val Leu Gln Lys Arg Gly Arg Glu Ile Arg Tyr Val
65 70 75 80
Leu His Thr Ala Ser Pro Tyr Tyr Asp Thr Thr Glu Tyr Glu Lys Asp
85 90 95
Leu Leu Ile Pro Ala Leu Glu Gly Thr Lys Asn Ile Leu Asn Ser Ile
100 105 110
Lys Lys Tyr Ala Ala Asp Thr Val Glu Arg Val Val Val Thr Ser Ser
115 120 125
Thr Thr Ala Ile Met Thr Leu Ala Lys Met Asp Asp Pro Ser Val Val
130 135 140
Phe Thr Glu Glu Ser Trp Asn Glu Ala Thr Trp Glu Ser Cys Gln Ile
145 150 155 160
Asp Gly Ile Asn Ala Ile Phe Ala Ser Arg Lys Phe Ala Glu Lys Ala
165 170 175
Ala Trp Glu Phe Thr Lys Glu Asn Glu Asp His Ile Lys Phe Lys Leu
180 185 190
Thr Thr Val Asn Pro Ser Trp Leu Phe Gly Pro Gln Leu Phe Asp Glu
195 200 205
Asp Val His Gly His Leu Asn Thr Ser Cys Glu Met Ile Asn Gly Leu
210 215 220
Ile His Thr Pro Val Asn Ala Ser Val Pro Asp Phe His Ser Ile Phe
225 230 235 240
Ile Asp Val Arg Asp Val Ala Leu Ala His Leu Tyr Ala Phe Gln Lys
245 250 255
Glu Asn Thr Ala Gly Lys Arg Leu Val Val Thr Asn Gly Lys Phe Gly
260 265 270
Asn Gln Asp Ile Leu Asp Ile Leu Asn Glu Asp Phe Pro Gln Leu Arg
275 280 285
Gly Leu Ile Pro Leu Gly Lys Pro Gly Thr Gly Asp Gln Val Ile Asp
290 295 300
Arg Gly Ser Thr Thr Asp Asn Ser Ala Thr Arg Lys Ile Leu Gly Phe
305 310 315 320
Glu Phe Arg Ser Leu His Glu Ser Val His Asp Thr Ala Ala Gln Ile
325 330 335
Leu Lys Lys Glu Asn Arg Leu
340
Claims (10)
1. A biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol, which is characterized by comprising the following steps: the method comprises the following steps:
carrying out mutation treatment on ketoreductase wild type genes: performing mutation treatment on the ketoreductase gene and the gene sequence of the ketoreductase as shown in Seq ID No.1 to obtain a ketoreductase mutant gene, wherein the gene sequence of the ketoreductase mutant is shown in Seq ID No. 2.
Adding enzyme cutting sites: inserting double enzyme cutting sites into a ketoreductase mutant gene;
preparing a recombinant plasmid: inserting the ketoreductase mutant gene into an expression vector to obtain a recombinant plasmid;
introducing a strain: introducing the recombinant plasmid with the ketoreductase gene into a strain to obtain a recombinant expression strain;
secretion and expression of the strains: inducing the recombinant expression strain in a culture solution for expression and then collecting an enzyme solution;
reaction: the enzyme solution is put into a water/organic biphase system to react to prepare (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol.
2. The process for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol according to claim 1, characterized in that: in the mutation treatment of the ketoreductase wild type gene, the mutation treatment mode is error-prone PCR.
3. The process for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol according to claim 1, characterized in that: in the added enzyme cutting sites, the double enzyme cutting sites are NdeI/HindIII.
4. The method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol as claimed in claim 1, wherein: in the preparation of the recombinant plasmid, the expression vector was pET21a (+) 22.
5. The method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol as claimed in claim 1, wherein: the introduced strain is BL21(DE 3).
6. The method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol as claimed in claim 1, wherein: in the secretion and expression of the strain, the culture solution is an LB culture medium.
7. (S) -2-chloro-1- (3, 4-difluorophenyl) as claimed in claim 1The biosynthesis method of ethanol is characterized by comprising the following steps: in the secretion and expression of the strain, induction culture is also included, when OD is in the culture medium600After 1.0, 0.2 miptg was added and the temperature was maintained at 30 ℃.
8. The method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol as claimed in claim 1, wherein: in the reaction, the water/organic two-phase system is a water/organic two-way system formed by mutually dissolving 40% of water and 60% of ethanol by mass fraction.
9. The method for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol as claimed in claim 1, wherein: in the reaction, the reaction system also comprises NADP.
10. The process for the biosynthesis of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol according to claim 9, characterized in that: the concentration of NADP is maintained at 0.05-1.0 mM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110877954.0A CN113502302A (en) | 2021-07-30 | 2021-07-30 | Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110877954.0A CN113502302A (en) | 2021-07-30 | 2021-07-30 | Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113502302A true CN113502302A (en) | 2021-10-15 |
Family
ID=78015422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110877954.0A Pending CN113502302A (en) | 2021-07-30 | 2021-07-30 | Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113502302A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233621A1 (en) * | 2004-02-04 | 2008-09-25 | Api Corporation | Method For Producing Alcohol and Carboxylic Acid Having Optical Activity |
| WO2012063126A2 (en) * | 2010-11-09 | 2012-05-18 | Actavis Group Ptc Ehf | Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material |
| CN109295020A (en) * | 2018-10-31 | 2019-02-01 | 安徽联创生物医药股份有限公司 | Ketoreductase and its application in synthesis (1S) -2- chloro- 1- (3,4- difluorophenyl) ethyl alcohol |
| CN109423484A (en) * | 2017-09-04 | 2019-03-05 | 尚科生物医药（上海）有限公司 | A kind of ketoreductase and its in the chloro- 1-(3,4- difluorophenyl of preparation (S) -2-) application on ethyl alcohol |
| CN110016467A (en) * | 2016-07-18 | 2019-07-16 | 中国科学院成都生物研究所 | Carbonyl reductase ChKRED20 mutant and application thereof |
| CN112410276A (en) * | 2020-11-27 | 2021-02-26 | 江苏阿尔法药业有限公司 | 2-chloro-1- (3, 4-difluorophenyl) ethanone reductase recombinant strain and construction method and application thereof |
| CN112941115A (en) * | 2021-03-30 | 2021-06-11 | 宿迁盛基医药科技有限公司 | Preparation method of ticagrelor chiral intermediate |
| US20210340505A1 (en) * | 2016-08-09 | 2021-11-04 | River Stone Biotech Llc | Biosynthesis of benzylisoquinoline alkaloids and benzylisoquinoline alkaloid precursors |
-
2021
- 2021-07-30 CN CN202110877954.0A patent/CN113502302A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233621A1 (en) * | 2004-02-04 | 2008-09-25 | Api Corporation | Method For Producing Alcohol and Carboxylic Acid Having Optical Activity |
| WO2012063126A2 (en) * | 2010-11-09 | 2012-05-18 | Actavis Group Ptc Ehf | Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material |
| CN110016467A (en) * | 2016-07-18 | 2019-07-16 | 中国科学院成都生物研究所 | Carbonyl reductase ChKRED20 mutant and application thereof |
| US20210340505A1 (en) * | 2016-08-09 | 2021-11-04 | River Stone Biotech Llc | Biosynthesis of benzylisoquinoline alkaloids and benzylisoquinoline alkaloid precursors |
| CN109423484A (en) * | 2017-09-04 | 2019-03-05 | 尚科生物医药（上海）有限公司 | A kind of ketoreductase and its in the chloro- 1-(3,4- difluorophenyl of preparation (S) -2-) application on ethyl alcohol |
| CN109295020A (en) * | 2018-10-31 | 2019-02-01 | 安徽联创生物医药股份有限公司 | Ketoreductase and its application in synthesis (1S) -2- chloro- 1- (3,4- difluorophenyl) ethyl alcohol |
| CN112410276A (en) * | 2020-11-27 | 2021-02-26 | 江苏阿尔法药业有限公司 | 2-chloro-1- (3, 4-difluorophenyl) ethanone reductase recombinant strain and construction method and application thereof |
| CN112941115A (en) * | 2021-03-30 | 2021-06-11 | 宿迁盛基医药科技有限公司 | Preparation method of ticagrelor chiral intermediate |
Non-Patent Citations (3)
| Title |
|---|
| TENG-YUN WEI等: "Development of an Enzymatic Process for the Synthesis of (S)-2-Chloro-1-(2,4-dichlorophenyl) Ethanol", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 * |
| 王明慧等: "酶催化拆分制备手性2-氯-1-（2,4-二氟苯基）乙醇及光学活性抗真菌药物的合成", 《有机化学》 * |
| 胡俊梅: "生物催化合成替格瑞洛手性中间体", 《中国知网》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6059784B2 (en) | Mutant enzyme and its use | |
| CN108048417B (en) | Ketoreductase mutant and application thereof | |
| CN111172124B (en) | Carbonyl reductase mutant and preparation thereofR) Application of (E) -4-chloro-3-hydroxy-butyrate | |
| CN106929521B (en) | Aldehyde ketone reductase gene recombination co-expression vector, engineering bacterium and application thereof | |
| CN108728421B (en) | Carbonyl reductase mutant and application thereof | |
| CN110551701B (en) | Carbonyl reductase mutant and application thereof in reduction of cyclopentadione compounds | |
| CN109266595B (en) | Construction and application of recombinant bacterium for producing L-2-aminobutyric acid by converting L-threonine | |
| CN112210549B (en) | Nitrilase mutant protein and application thereof in catalytic synthesis of (R) -3-substituted-4-cyanobutyric acid compounds | |
| CN112921014B (en) | T7RNA polymerase mutant, mRNA, gene, expression vector and cell | |
| CN109355266B (en) | Imine reductase mutant and application thereof in synthesis of optically active 1-substituted-tetrahydroisoquinoline derivative | |
| CN113073089A (en) | Novel method for improving enzyme activity of NMN biosynthetic enzyme Nampt | |
| JP6695802B2 (en) | Mutant enzyme and its use | |
| CN114480512A (en) | Application of oxidoreductase and mutant thereof in biosynthesis of nootkatone | |
| CN113502302A (en) | Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol | |
| CN111100851B (en) | Alcohol dehydrogenase mutant and application thereof in synthesis of chiral diaryl alcohol compound | |
| CN111575326A (en) | Method for synthesizing (1S, 5R) -dicyclic lactone by enzyme catalysis | |
| CN114591923B (en) | Cannabidiol synthetase mutant and construction method and application thereof | |
| CN113604444B (en) | Carboxylic acid reductase mutant with improved catalytic activity, encoding gene thereof, genetically engineered bacterium and application | |
| CN114854714A (en) | Kidney bean source epoxide hydrolase mutant, gene, vector, engineering bacterium, preparation method and application | |
| CN112410353B (en) | fkbS gene, genetic engineering bacterium containing fkbS gene, and preparation method and application of fkbS gene | |
| CN114507650A (en) | Leucine dehydrogenase mutant and application thereof in synthesis of (S) -o-chlorophenylglycine | |
| CN106636019B (en) | High-efficiency catalytic synthesis of (S) -phenyl glycol by using (S) -carbonyl reductase oligomer mediated by Sortase A | |
| JPWO2013002277A1 (en) | Enzyme function modification method and variant thereof | |
| CN110004119B (en) | -ketoester reductase mutant and application thereof in catalyzing and synthesizing (R) -alpha-lipoic acid precursor | |
| CN112852770B (en) | Alcohol dehydrogenase mutant and application thereof in preparing chiral diaryl alcohol compound by efficient asymmetric reduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |